Drugs.com - Clinical Trials

Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial

Thu, 09 Jul 2009 20:51:03 GMT

SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology,...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

Thu, 09 Jul 2009 18:58:21 GMT

Findings Further Support Leptin as Part of Company's Integrated Neurohormonal Therapy for Obesity (INTO) Strategy SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced positive results from a 28-week...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax) for the Treatment of Inhalation Anthrax

Thu, 09 Jul 2009 18:58:20 GMT

- Biologics License Application pending for first-in-class treatment for inhalation anthrax - - HGS has delivered 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use under a contract with BARDA - ROCKVILLE, Md.,...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

Thu, 09 Jul 2009 18:53:30 GMT

Expected and Manageable Safety Profile Demonstrated in TASKi2 SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that R788 (fostamatinib disodium) produced significant clinical...

Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials

Thu, 09 Jul 2009 13:10:35 GMT

BOULDER, Colo.--(BUSINESS WIRE)--Jul 8, 2009 - Array BioPharma Inc. (NASDAQ: ARRY) today announced top-line results from its Phase 1 seven-day dose escalation trial up to 1,200 mg daily of p38 inhibitor, ARRY-797, in healthy volunteers. In addition,...

Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting

Thu, 09 Jul 2009 12:44:37 GMT

DUBLIN--(BUSINESS WIRE)--Jul 8, 2009 - Elan Corporation, plc (NYSE: ELN) today announced multiple presentations at the 2009 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2009) in Vienna, Austria. Elan and...

Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles

Thu, 09 Jul 2009 12:05:42 GMT

NEWARK, Calif.--(BUSINESS WIRE)--Jul 9, 2009 - Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow's feet wrinkles, demonstrated efficacy...

Vical TransVax CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial

Wed, 08 Jul 2009 22:04:12 GMT

Conference Call and Webcast Scheduled for 11 a.m. ET SAN DIEGO, July 8, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that its TransVax(tm) therapeutic DNA cytomegalovirus (CMV) vaccine provided promising results...

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

Wed, 08 Jul 2009 13:11:08 GMT

TURKU, Finland, July 03, 2009 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream,...

ARYx Therapeutics Announces Results of Phase 2/3 Clinical Trial on Anticoagulant Agent Tecarfarin

Wed, 08 Jul 2009 12:50:41 GMT

Efficacy of Tecarfarin Mirrors Earlier Studies While Primary Endpoint Missed FREMONT, Calif.--(BUSINESS WIRE)--Jul 8, 2009 - ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced results from its Phase 2/3 clinical...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

Wed, 08 Jul 2009 02:50:52 GMT

Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences QUEBEC CITY, July 7 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

Wed, 08 Jul 2009 02:49:51 GMT

Largest efficacy trial of a cervical cancer vaccine showed Cervarix(R) protects against the five most common cancer-causing virus types LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is...

EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease

Wed, 08 Jul 2009 02:43:22 GMT

WATERTOWN, Mass., July 7 /PRNewswire/ -- WHAT: EnVivo Pharmaceuticals to share results from its Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. WHEN: ...

Denosumab Demonstrates Superiority Over Zometa in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

Wed, 08 Jul 2009 02:16:26 GMT

First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the Advanced Cancer Setting Meets Primary and Secondary Endpoints THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a...

Presse Release: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.

Tue, 07 Jul 2009 13:27:59 GMT

- Marked improvement in symptoms even after short period of treatment - Over 240 individuals treated with BT-061 Dreieich, 7 July 2009. After the ongoing clinical development in the indication of psoriasis has provided evidence of the efficacy of...

Published in The Lancet...Cervarix protects against the five most common cancer-causing virus types

Tue, 07 Jul 2009 13:19:44 GMT

LONDON, Tues 7 July: The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline’s Cervarix® is highly effective at protecting...

Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax CMV Vaccine Phase 2 Interim Efficacy Results

Tue, 07 Jul 2009 13:04:41 GMT

SAN DIEGO, July 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax(tm)...

XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes

Tue, 07 Jul 2009 13:03:56 GMT

BERKELEY, Calif., Jul 7, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced plans to hold a conference call and webcast on July 14, 2009 at 4:30 pm...

Aeolus Pharmaceuticals' AEOL 10150 Significantly Increases Survival in Mice Exposed to Radiation when Administered After Exposure

Mon, 06 Jul 2009 20:29:07 GMT

Data to Be Presented at the 55th Annual Meeting of the Radiation Research Society in October MISSION VIEJO, Calif.--(BUSINESS WIRE)--Jul 6, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) announced today that data from a study in which...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus Compared to NPH

Mon, 06 Jul 2009 13:48:24 GMT

- Long-term study found no increased progression of retinopathy in Lantus(R) over NPH treatment regimen - BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the...

Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion

Thu, 02 Jul 2009 20:42:21 GMT

-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2009 - Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection)...

iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment

Thu, 02 Jul 2009 20:28:00 GMT

VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer-reviewed scientific...

Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics

Thu, 02 Jul 2009 13:46:49 GMT

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Jul 1, 2009 - Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of...

Lu AA24530 shows positive results in major depressive disorder phase II study

Thu, 02 Jul 2009 13:21:08 GMT

COPENHAGEN, July 2, 2009--H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD). The primary objective of the study...

Sucampo Reports Top-Line Results of Phase 2 Clinical Trial of Cobiprostone for Prevention of NSAID-Induced Gastrointestinal Injuries

Thu, 02 Jul 2009 12:35:23 GMT

BETHESDA, Md.--(BUSINESS WIRE)--Jul 1, 2009 - Sucampo Pharma Americas, Inc., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today reported top-line results from its phase 2 clinical trial of orally administered...

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases

Wed, 01 Jul 2009 19:35:36 GMT

- Results Demonstrate Positive Proof of Mechanism SAN DIEGO, June 30/PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also...

Study Showed Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

Wed, 01 Jul 2009 19:20:09 GMT

VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD HOLLYWOOD, Fla., July 1 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company,...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

Wed, 01 Jul 2009 19:16:31 GMT

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE:...

New Review on Prostvac Published by Key Investigators From NCI

Wed, 01 Jul 2009 19:16:21 GMT

KVISTGAARD, Denmark, July 1/PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most...

Pharming Confirms Positive Results From Fina l Analysis Of Rhucin Studies

Wed, 01 Jul 2009 13:51:39 GMT

Leiden, The Netherlands, July 1, 2009. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that, as part of the activities for the regulatory submission files, it has now...

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta (Formerly Lymphostat-B in Systemic Lupus Erythematosus

Wed, 01 Jul 2009 13:41:47 GMT

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials...

New Data Supports Significant Economic and Clinical Value of Menopur in IVF

Wed, 01 Jul 2009 02:09:21 GMT

- "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" AMSTERDAM, The Netherlands, June 30/PRNewswire/ --New data from an economic analysis presented today at this year's European Society of Human...

Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease

Wed, 01 Jul 2009 02:08:41 GMT

Liestal, Switzerland, June 30, 2009 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive data from its Phase IIb study (FJORD). The key finding of the trial is...

New Data: Efficacy and Responder Analyses of Divigel (estradiol gel) 0.1 percent for the Treatment of Menopause

Wed, 01 Jul 2009 02:00:54 GMT

Data shows a very high percentage of women responded favorably to a bioidentical and FDA approved hormone therapy for hot flashes MAPLE GROVE, Minn., June 30 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. presented the results of a secondary...

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

Wed, 01 Jul 2009 01:35:58 GMT

Prospective Study Seeks to Assess RSV Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance its commitment to pediatric research...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

Wed, 01 Jul 2009 00:17:39 GMT

S. MAMEDE DO CORONADO, Portugal, June 29/PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

Wed, 01 Jul 2009 00:10:46 GMT

SOUTHAMPTON, England, June 29/PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of...

Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response

Tue, 30 Jun 2009 21:30:10 GMT

SAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in...

Inovio assesses vaccine against swine flu

Tue, 30 Jun 2009 20:36:24 GMT

Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines Against “Swine” Influenza A (H1N1) Collaboration of vaccine experts to assess DNA vaccines designed to provide broad...

DuoCort: New chronotherapy for adrenal insufficiency

Tue, 30 Jun 2009 20:04:27 GMT

DuoCort: New chronotherapy for adrenal insufficiency Helsingborg, Sweden, June 29th 2009 / b3c newswire - DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of...